Literature DB >> 12776159

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

M Figini1, R Ferri, D Mezzanzanica, M Bagnoli, E Luison, S Miotti, S Canevari.   

Abstract

The alpha-folate receptor (FR) is selectively overexpressed in 90% of nonmucinous ovarian carcinomas, whereas no expression is detectable in normal ovarian surface epithelium (OSE). Indirect evidence suggests that FR expression is associated with tumor progression and affects cell proliferation. To evaluate better the role of FR, we developed an approach based on intracellular expression of single-chain (sc) antibodies (intrabody) to downmodulate membrane expression of FR in ovary cancer cells. IGROV-1 and SKOV3 ovarian carcinoma cell lines were transfected with an anti-FR intrabody. Transfectants and parental cells were tested for FR, integrins and anti-FR intrabody expression by fluorescence-activated cell sorting (FACS), reverse transcription and polymerase chain reaction (RT-PCR) and/or immunoblotting. Cell growth characteristics and adhesion properties were evaluated in liquid, semisolid and organotypic cultures. The anti-FR scFv inhibited FR expression from 60 to 99%. At physiological concentrations of folate, proliferation varied directly as a function of FR expression. FR downmodulation was accompanied by reduced colony-forming ability in soft agar, morphological change of the cells, significant enhanced adhesion to laminin or Matrigel, a two- to three-fold increase in alpha6beta4 integrin expression, and a marked reduction in laminin production. In three-dimensional organotypic cultures, anti-FR intrabody-transfected IGROV1 cells grew as a single-ordered layer, reminiscent of normal OSE growth in vivo. In conclusion, the anti-FR intrabody reverses the transformed phenotype in ovary cancer cells and may provide an efficient means to inhibit selectively the growth of these cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776159     DOI: 10.1038/sj.gt.3301962

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  21 in total

1.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

2.  Role of farletuzumab in epithelial ovarian carcinoma.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Authors:  Yunfei Wen; Whitney S Graybill; Rebecca A Previs; Wei Hu; Cristina Ivan; Lingegowda S Mangala; Behrouz Zand; Alpa M Nick; Nicholas B Jennings; Heather J Dalton; Vasudha Sehgal; Prahlad Ram; Ju-Seog Lee; Pablo E Vivas-Mejia; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-11-21       Impact factor: 12.531

Review 4.  Emerging roles for folate receptor FOLR1 in signaling and cancer.

Authors:  Fathima Zahra Nawaz; Edward T Kipreos
Journal:  Trends Endocrinol Metab       Date:  2022-01-31       Impact factor: 12.015

5.  MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.

Authors:  Zhen J Wang; Sophie Boddington; Michael Wendland; Reinhard Meier; Claire Corot; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2008-03-21

Review 6.  Exploiting the folate receptor α in oncology.

Authors:  Mariana Scaranti; Elena Cojocaru; Susana Banerjee; Udai Banerji
Journal:  Nat Rev Clin Oncol       Date:  2020-03-09       Impact factor: 66.675

7.  Folate receptor alpha as a tumor target in epithelial ovarian cancer.

Authors:  Kimberly R Kalli; Ann L Oberg; Gary L Keeney; Teresa J H Christianson; Philip S Low; Keith L Knutson; Lynn C Hartmann
Journal:  Gynecol Oncol       Date:  2008-01-28       Impact factor: 5.482

8.  Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors.

Authors:  Joanne Kotsopoulos; Jonathan L Hecht; Jonathan D Marotti; Linda E Kelemen; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

9.  Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Authors:  Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-03-09

10.  Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.

Authors:  Michelle K Y Siu; Daniel S H Kong; Hoi Yan Chan; Esther S Y Wong; Philip P C Ip; LiLi Jiang; Hextan Y S Ngan; Xiao-Feng Le; Annie N Y Cheung
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.